The raw material for blood plasma industry is the liquid that is a component of blood called blood plasma. Blood plasma makes up approximately 55% of the total blood volume. Blood plasma is pale yellow in color and consists of water, proteins and salt. Those proteins are used to produce medicinal products for treatment of a variety of life-threatening diseases, illnesses and conditions. These plasma-derived medications are the standard course of treatment for thousands of people, in more than 100 countries across the globe, who need the treatment to improve their health and lead productive lives.

The chief components of the global blood plasma market are immunoglobulin, albumin, factor VIII and Alpha-1 proteinase inhibitor (A1PI) or alpha-1 antitrypsin (AAT). These components are proteins and antibodies that are extracted from the fractionated blood plasma and used for the treatment of various indications.

The key factors which are anticipated to drive this market include rising healthcare expenditure, growing demand for polyvalent immunoglobulin and increasing market for albumin in the Asia-pacific. Some of the noteworthy progresses of this industry include the new potential for raising AATD diagnosis and introduction of extended half-life products for hemophilia. However, the growth of respective industry is challenged by the high cost of production that discourages new entrants, shrinking market for plasma-derived factor VIII, high industry regulation in the emerging market and increasing threat of substitutes.

The report provides a wide-ranging study of global blood plasma market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are examined in depth. The global blood plasma market is highly competitive consisting of several large conglomerates including Baxter international, CSL, Grifols, Octapharma etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

3.1 The US Plasma Fractionation Capacity3.2 The US Blood Derivative Usage by Category3.3 The US Immunoglobulin Market 3.3.1 The US Immunoglobulin Market Revenue 3.3.2 The US Immunoglobulin Market by Volume 3.3.3 The US Immunoglobulin Market Volume by Category 3.3.4 The US Intravenous Immunoglobulin (IVIG) Market by Volume 3.3.5 The US Subcutaneous Immunoglobulin (SCIG) Market by Volume 3.3.6 The US IV/SCIG Market by Medical Specialty